The paper reviews new chemotherapy strategies for intermediate and advanced stages of Hodgkin's disease as well as the implications of recent biological concepts and mathematical models which appear useful in the interpretation and design of new treatments. The development and the application of the Adriamycin-bleomycin-vinblastine-dacarbazine (ABVD) combination was based on critical reevaluati...

Introduction: PET-adapted ABVD with deferred intensification is the favored therapy for most patients advanced Hodgkin Lymphoma (HL), while upfront (‘first hit’) escBEACOPP remains an option in high-risk disease. These strategies are challenged by brentuximab vedotin (BV)-based AVD regimen due to superior outcomes versus ABVD. The FIL-Rouge trial (NCT03159897) was designed implement ‘first-hit’...

Brentuximab vedotin (BV) as consolidation treatment in patients with stage I/II classical Hodgkin's lymphoma and a positive FDG-PET after 2 cycles (PET-2) of ABVD: LYSA phase study. Introduction: Early-stage Hodgkin (cHL) is highly curable chemotherapy radiotherapy (RT). However, interim PET-2 have poorer prognosis require intensification. Indeed, the H10 trial (André et al., 2017) showed that ...

1. Nogová L, Reineke T, Brillant C, et al; German Hodgkin Study Group. Lymphocytepredominant and classical Hodgkin’s lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol. 2008;26(3):434-439. 2. Savage KJ, Skinnider B, Al-Mansour M, Sehn LH, Gascoyne RD, Connors JM. Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgk...

Abstract The role of consolidation radiotherapy (RT) for bulky lesions is controversial in patients with advanced-stage Hodgkin lymphoma who achieve complete metabolic response (CMR) after doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD)–based chemotherapy. We present the final results Fondazione Italiana Linfomi HD0801 trial, which investigated potential benefit RT that setting. In this...

Hodgkin lymphoma (HL) is a hematopoietic malignancy of B-cells that has bimodal distribution with respect to age and incidence. With the introduction doxorubicin (Adriamycin), bleomycin, vinblastine, dacarbazine (ABVD) radiation combined, prognosis HL significantly improved, five-year survival rates approaching 95%. While become highly curable, side effect profiles ABVD are dire warrant continu...

Presently Hodgkin's lymphoma can be cured in at least 80% of patients. The major challenge to the clinician in 2005 is how to cure the disease while inducing the least irreversible toxicity. This review focuses on clinical trials and institutional experiences to identify the best choice of treatment, individualized to the stage of the lymphoma permitting minimization of late toxicity such as in...

BACKGROUND Ovarian function was studied in Danish patients who had ovarian tissue cryopreserved, and the patients' experiences with the procedure were investigated. METHODS There were 92 women who had an entire ovary removed for cryopreservation 18-75 months earlier. Reasons included: breast cancer (n = 31; 34%), Hodgkin's lymphoma (n = 23; 25%), bone marrow transplantation (BMT) (n = 19; 21%...